Gilead Sciences (GILD) Receives European Approval for Yeytuo, its Twice-Yearly HIV Prevention Drug
Approval Background and Clinical Performance
Gilead Sciences' (GILD) new HIV pre-exposure prophylaxis (PrEP) drug, Yeytuo (active ingredient: lenacapavir), received final marketing authorization from the European Medicines Agency (EMA) on August 25, 2025. This approval is based on innovative data from the PURPOSE 1 Phase 3 trial, which demonstrated a 0% infection rate in cisgender women, and the PURPOSE 2 Phase 3 trial, which included cisgender men and showed a 96% reduction in infection rates. Yeytuo is the first capsid inhibitor, targeting the HIV-1 capsid protein essential for viral replication, demonstrating its technological superiority. Compared to existing once-daily oral medications, it presents overwhelming clinical data in terms of ease of use and efficacy, allowing it to quickly pass regulatory hurdles.
Differentiation and Positioning Compared to Competing Drugs
Yeytuo is being developed as a twice-yearly (every six months) injectable formulation, with the potential to revolutionize the existing treatment paradigm. Compared to Apretude (active ingredient: cabotegravir), ViiV Healthcare's leading product in the market, which is administered every two months, Yeytuo increases the administration interval threefold, maximizing patient adherence. It completely solves the concerns of missed doses and social stigma associated with daily oral PrEP medications such as Truvada and Descovy. By offering the convenience of twice-yearly preventative injections, it is well-positioned to capture a dominant market share by increasing voluntary prevention rates among high-risk patients.
Market Size and Financial Expectations
The global HIV prevention and treatment market is valued at approximately $35.2 billion in 2025, with the PrEP market being the fastest-growing segment. Gilead recorded $20.8 billion in total HIV treatment sales in 2025, and forecasts that global PrEP sales, including Yeytuo's U.S. brand name, Yeztugo, will reach approximately $800 million in 2026. With the convenience of twice-yearly injections, new patient acquisition is expected to accelerate, making Yeytuo highly likely to become a blockbuster drug with annual sales exceeding $1 billion within a few years. This will undoubtedly be a key driver in offsetting Gilead's patent expiration risks and maintaining its dominant position in the HIV market.
Challenges and Reimbursement Barriers in the European Market
However, to achieve immediate commercial success in the European market, Gilead must overcome significant hurdles in terms of pricing and reimbursement negotiations in each country. Europe has a conservative national healthcare system and requires strict proof of cost-effectiveness. Overcoming price competition with existing, low-cost generic oral medications and demonstrating that the expensive injectable is cost-effective is a key challenge for initial market penetration. Gilead plans to establish flexible pricing agreements with each government and quickly build a supply chain and monitoring and training system for healthcare providers to prevent supply chain disruptions.
The European approval of Yeytuo, with its innovative twice-yearly administration, differentiates it from ViiV Healthcare's bi-monthly Apretude and will be a turning point in reshaping the global $35.2 billion HIV market. The overwhelming preventative efficacy, with infection rates close to 0% demonstrated in Phase 3 trials (PURPOSE 1 and 2), perfectly overcomes the adherence limitations of existing standard treatments such as oral Truvada, and is expected to maximize voluntary prevention participation among high-risk groups. In the short term, it will drive the achievement of the global sales target of $800 million in 2026, and in the medium to long term, it will serve as a key cash cow for Gilead Sciences (GILD), filling the revenue gap of existing portfolios facing patent expiration. Furthermore, the approval of the first HIV capsid protein inhibitor will promote the development of subsequent pipelines and serve as a research milestone in establishing new standards for the next generation of antiretroviral therapies.
Source: EMA (ema)